Selectively substituted quinoline compounds
US10087174B2 · kind B2 · utility
0Cited by
74References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 7, 2017 |
| Grant date | Oct 2, 2018 |
| Priority date | — |
| Expiry date | Aug 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/07
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.